Instructions for Estrovagin (Estriol) vaginal suppositories 0,5 mg
English product name
Estrovagin
Release Form Estrovagin
Rectal suppositories
Description Estrovagin
Rectal suppositories are designed in the form of a torpedo, from white to light brown.
1 soupp.
estriol (micronized) 500μg
Auxiliary substances: Vitepsol W35 - sufficient quantity to produce a 2 g suppository.
5 pcs. - packages of box-type contour (2) - cardboard packs.
ATC codes
G03CA04 Estriol
Clinical-pharmacological groups / Group affiliation
Estrogenic preparation
Active substance Estrovagin
estriol micronized
Pharmaco-therapeutic group Estrovagin
Estrogen
Testimony Estriol
- CGT for treatment of lower urinary and genital tract atrophy related to estrogenic failure;
- pre- and post-operative treatment of postmenopausal women with vaginal access;
- diagnostic for unclear results of cervical cytology (suspected tumour process)
- against the background of atrophic changes.
Method of use, course and dosage Estriol
Intravaginally administered.
The dose is 500 micrograms per day. The application procedure is set individually, depending on the indications and clinical situation.
Pharmacological effect Estriol
Estrogen, an analog of the natural female hormone. Replenishes estrogen deficiency in postmenopausal women and relieves postmenopausal symptoms. It is most effective in the treatment of urinary disorders. In the atrophic mucosa of the lower urinary tract, estriol promotes the normalization of the urinary tract epithelium and contributes to the restoration of normal microflora and physiological pH in the vagina.
The invention makes it possible to increase the resistance of epithelial cells of the genitourinary tract to infections and inflammation, thereby reducing complaints such as pain during sexual intercourse, dryness and itching in the vagina, to reduce the probability of vaginal infections and urinary tract infections, to normalise urination and to prevent urinary incontinence.
- Nosology Estrovagin (ICD codes)
- N95.1
- Menopause and menopause in women
- N95.2
- Postmenopausal atrophic vaginitis
- N95.3
- Conditions associated with artificially induced menopause
- Z03
- Medical observation and evaluation in the event of a suspected disease or pathological condition
- Z51.4
- Preparatory procedures for follow-up treatment or examination not classified elsewhere
